On January 7, 2008, Orexigen™ Therapeutics, Inc., announced the 48-week results of the Phase IIb clinical trial of it's weight loss drug, Empatic™. Weight loss through 48 weeks for the highest Empatic dosage arm, in the intent-to-treat, was 14.0% and 15.1%, respectively in the double blind extension and completer groups.
This was Orexigen's first large, multi-center trial of Empatic™, formally known as Excalia™. Empatic™ is a combination of zonisamide and bupropion SR.
Information in this post came from an Orexigen Press release. You can view the entire release at http://ir.orexigen.com/releasedetail.cfm?ReleaseID=284849.
Technorati Tags: Empatic™ Excalia™ Weight Loss Pills Weight Loss DrugsObesityEmpatic™
Saturday, March 8, 2008
Subscribe to:
Comments (Atom)